Focused on developing anti-infectives for immunocompromised patients, AiCuris is not limited to one proprietary platform or technology, but always aims to identify novel approaches. Current in-licensing interests comprise novel anti-virals and anti-fungals in late preclinical to clinical development, aiming to increase the quality of life of patients with low immune defenses.

Out-licensing Ι

A strong 3rd generation HBV Capsid Assembly Modulator

Link to presentation

Out-licensing ΙΙ

A resistance-breaking anti-bacterial with novel target in lipid A biosynthesis

Link to presentation

If you or your company are interested in partnering with AiCuris, please contact us.